Gautam Patel Joins Group in Amneal Pharma, Signaling Potential Activism

TL;DR

**Patel's 13D/A shows he's now part of a group, watch for potential activist moves at Amneal!**

AI Summary

Gautam Patel, a significant shareholder in Amneal Pharmaceuticals, Inc., filed an Amendment No. 5 to his Schedule 13D on January 1, 2024. This filing indicates that Mr. Patel is now part of a group, which is a crucial update for investors. This matters because being part of a group can signal a more coordinated effort to influence the company's direction, potentially leading to strategic changes or increased shareholder activism, which could impact the stock's value.

Why It Matters

This filing signals a potential shift in shareholder influence at Amneal Pharmaceuticals, as Gautam Patel is now part of a group, which could lead to coordinated actions impacting company strategy and stock performance.

Risk Assessment

Risk Level: medium — The formation of a shareholder group can introduce uncertainty regarding future corporate actions, potentially leading to volatility in the stock price.

Analyst Insight

Investors should monitor future filings and company announcements from Amneal Pharmaceuticals closely for any signs of strategic shifts or shareholder engagement resulting from Gautam Patel's new group affiliation. This could signal potential changes in governance or operational strategy.

Key Numbers

• 03168L105 — CUSIP Number (Identifies Amneal Pharmaceuticals, Inc.'s Class A Common Stock.)
• Amendment No. 5 — Filing Amendment Number (Indicates this is the fifth amendment to Gautam Patel's original Schedule 13D filing.)

Key Players & Entities

• Gautam Patel (person) — Reporting Person and significant shareholder of Amneal Pharmaceuticals, Inc.
• Amneal Pharmaceuticals, Inc. (company) — The subject company whose Class A Common Stock is being reported on.
• $0.01 (dollar_amount) — Par value of Amneal Pharmaceuticals, Inc. Class A Common Stock.
• January 1, 2024 (date) — Date of the event requiring the filing of this Schedule 13D/A.

Forward-Looking Statements

• Gautam Patel, as part of a group, will likely engage in discussions with Amneal Pharmaceuticals' management regarding strategic direction. (Amneal Pharmaceuticals, Inc.) — medium confidence, target: Q2 2024
• The formation of this group could lead to increased shareholder activism or proposals at future shareholder meetings. (Amneal Pharmaceuticals, Inc.) — medium confidence, target: Next Annual Meeting

FAQ

Key Financial Figures

• $0.01 — ssuer) Class A Common Stock, par value $0.01 (Title of Class of Securities) 03168L
• $15.01 — pon exercise of options exercisable for $15.01 per share, which expire on May 7, 2028
• $14.05 — pon exercise of options exercisable for $14.05 per share, which expire on May 6, 2029.

Filing Documents

• sc13d-a.htm (SC 13D/A) — 62KB
• 0000898432-24-000009.txt ( ) — 63KB

Identity and Background

Item 2. Identity and Background.

of the Schedule 13D is hereby deleted in its entirety and replaced with the following

Item 2 of the Schedule 13D is hereby deleted in its entirety and replaced with the following: The Schedule 13D is being filed by Gautam Patel (the "Reporting Person"). The present principal occupation of the Reporting Person is serving as President of Cepheid Capital, LLC. Prior to January 1, 2024, the Reporting Person also served as President of Tattva Fiduciary Company ("Tattva") and was the sole owner of Tattva. The T-Twelve Legacy Trust dated December 8, 2006 (the "T-Twelve Trust") is an irrevocable trust governed by the laws of the State of Nevada, of which Tattva is the sole trustee. The Falcon Trust dated December 11, 2001 (the "Falcon Trust") is an irrevocable trust governed by the laws of the State of Nevada, of which Tattva is the sole trustee. The AHPPCB Legacy Trust U/A February 1, 2014 (the "Legacy Trust" and, together with the T-Twelve Trust and the Falcon Trust, the "Trusts") is an irrevocable trust governed by the laws of the State of Nevada, of which Tattva is the sole trustee. Tattva is also the sole trustee of certain other trusts that hold Class A Common Stock of the New Issuer. The business address of the Reporting Person is 1 John Street, #9D, Brooklyn, NY 11201. The business address of each of the Trusts is c/o Sierra Fiduciary Support Services, 100 West Liberty Way, 10th Floor, Reno, Nevada 89501. During the last five years, the Reporting Person has not been (i) convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or

Purpose of Transaction

Item 4. Purpose of Transaction. The disclosure in Item 4 is hereby amended and supplemented by adding the following: On January 1, 2024, the Reporting Person entered into a Stock Purchase and Sale Agreement with Akram Mahesh ("Mahesh"), pursuant to which the Reporting Person sold to Mahesh 1,000 shares of the common stock of Tattva, which constitute all of the issued and outstanding common stock of Tattva (the "Sale Transaction"). In connection with the Sale Transaction, the Reporting Person also resigned from his positions as Director, President, Discretionary Committee Member and Investment Committee Member of Tattva, effective as of January 1, 2024 (the "Resignation"). As a result of the Sale Transaction and the Resignation, the Reporting Person no longer has sole or shared voting or dispositive power over, or deemed beneficial ownership of, any of the shares of Class A Common Stock of the New Issuer held by any trusts (including the Trusts) of which Tattva is the sole trustee. CUSIP No. 03168L105 13D Page 3 of 4 The Reporting Person is a beneficiary of the Legacy Trust. Following the effectiveness of the Sale Transaction and the Resignation, on January 1, 2024, the Reporting Person received a distribution of 1,598,115 shares of Class A Common Stock of the New Issuer from the Legacy Trust.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. The disclosure in Item 5 is hereby amended and restated in its entirety to read as follows: (a) – (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Class A Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 306,544,199 shares of Class A Common Stock outstanding, as described in the Agreement and Plan of Merger filed as Exhibit 2.1 to the Issuer's Form 8-K, filed on November 8, 2023: Reporting Person Amount beneficially owned Percent of class Sole power to vote or to direct the vote Shared power to vote or to direct the vote Sole power to dispose or to direct the disposition Shared power to dispose or to direct the disposition Gautam Patel 2,025,454 0.07 2,025,454 0 2,025,454 0 The Reporting Person owns directly (i) 1,972,433 shares of Class A Common Stock, (ii) 24,977 shares of Class A Common Stock issuable upon exercise of options exercisable for $15.01 per share, which expire on May 7, 2028 and (iii) 28,044 shares of Class A Common Stock issuable upon exercise of options exercisable for $14.05 per share, which expire on May 6, 2029. (c) The information set forth in Item 4 of this Amendment No. 5 is incorporated by reference herein. (d) None. (e) January 1, 2024. CUSIP No. 03168L105 13D Page 4 of 4

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : January 3, 2024 /s/ Gautam Patel Gautam Patel

View Full Filing

View this SC 13D/A filing on SEC EDGAR